64.6 F
New York
Thursday, October 22, 2020

Clovis Oncology Inc. (NASDAQ:CLVS) Finding Zero Support

Must read

The Unprecedented Rise of IQVIA Holdings Inc. (NYSE:IQV)

IQVIA Holdings Inc. (IQV) shares are trading at higher $173.50 and the avg recommendation for the stock is Strong Buy, while the current analyst...

The Forecast Just Changed on SunLink Health Systems Inc. (AMEX:SSY)

SunLink Health Systems Inc. (SSY) shares are trading at higher $1.29. To add more color to this target, the company’s high over the last...

American Axle & Manufacturing Holdings Inc. (NYSE:AXL) is Holding Steady

American Axle & Manufacturing Holdings Inc. (AXL) shares are trading at higher $6.67 and the avg recommendation for the stock is Moderate Buy, while...

Oncolytics Biotech Inc. (NASDAQ:ONCY) is Waving the Bull Flag

Oncolytics Biotech Inc. (ONCY) shares are trading at higher $2.27. To add more color to this target, the company’s high over the last year...

Clovis Oncology Inc. (CLVS) shares are trading at lower $5.68 and the avg recommendation for the stock is Hold, while the current analyst price target stands at $9.00.

To add more color to this target, the company’s high over the last year is $17.37 and the low is $2.93. Over the last 52 weeks, CLVS is up 79.18% while the S&P 500 is up 18.28%. The catalyst for this interesting swing was the company’s recent earnings report.

A Notable Earnings Report

In the last quarter, CLVS reported a profit of $29.49 million. Clovis Oncology Inc. also saw revenues increase to $39.89 million. In addition, CLVS has free cash flow of -$142.43 million as of 06-2020. The company’s EBITDA came in at -$80.05 million which compares well with its peers.

CLVS Return on Equity (ROE) is 316.90%, and its Return on Assets is -58.90%. All told, it is clear that, CLVS needs to be on your watchlist.

Find out when CLVS reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.

Of course, we must look beyond the financials and question how well those numbers represent the sustainable earnings power of the business. Investors need to know how sustainable this current run. CLVS has a short ratio of 8.12 and outstanding shares of 88.20M.

Company Outlook

CLVS has seen increased volume after this news and investors are putting their support behind the value proposition. Furthermore, 10-day volume stands at 2.91 million and more growth is possible in the weeks ahead. Traders will also note the company’s earnings per share came in at -6.07. Clovis Oncology Inc. CLVS also noted assets of $628.21 million at the end of the last quarter. Investors should also keep an eye on sector updates as CLVS has historically followed its peers on positive news.

All told, Clovis Oncology Inc. CLVS has strung together solid data and demonstrated underlying fundamentals. At its current valuation, CLVS represents an interesting risk/reward case. Traders should stay tuned to see if this recent report will push the stock to test recent resistance levels.

Clovis Oncology Inc. CLVS is now commanding a market cap of 515.52M and a float of 85.08M. CLVS is increasing its credibility in this sector and that could lead to more upside down the line. Sign-up for continuing coverage on shares of CLVS stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in CLVS, either long or short, and we have not been compensated for this article.

Latest article

Philip Morris International Inc. (NYSE:PM) Stock is Soaring, Here is Why

Philip Morris International Inc. (PM) shares are trading at higher $73.82 and the avg recommendation for the stock is Strong Buy, while the current...

Plains All American Pipeline L.P. (NYSE:PAA) is Holding Steady

Plains All American Pipeline L.P. (PAA) shares are trading at lower $6.49 and the avg recommendation for the stock is Moderate Buy. To add...

Investor Confidence is Rising for CEMEX S.A.B. de C.V. (NYSE:CX)

CEMEX S.A.B. de C.V. (CX) shares are trading at higher $4.23 and the avg recommendation for the stock is Moderate Buy, while the current...

Aphria Inc. (NASDAQ:APHA) is Gaining Momentum on Earnings Catalyst

Aphria Inc. (APHA) shares are trading at higher $4.68. To add more color to this target, the company’s high over the last year is...

The Rejuvenation of AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca PLC (AZN) shares are trading at lower $51.57 and the avg recommendation for the stock is Strong Buy, while the current analyst price...